| 06/17 | PFIZER : Price Target From RBC Lifted to $44 From $43 as Firm Raises Vaccine Re.. | MT |
| 06/15 | ANALYST RECOMMENDATIONS : Anglo American, Pfizer, Rolls-Royce, Nike, Oatly... | |
| 06/15 | PFIZER INC : Berenberg reiterates its Neutral rating | MD |
| 05/24 | TODAY'S ANALYST RECOMMENDATIONS : Applied Materials, easyJet, Pfizer, Ralph Laur.. | |
| 05/24 | PFIZER INC : Goldman Sachs reiterates its Neutral rating | MD |
| 05/24 | PFIZER INC : JP Morgan reiterates its Neutral rating | MD |
| 05/13 | PFIZER INC : Gets a Neutral rating from Goldman Sachs | MD |
| 05/10 | PFIZER : Berenberg Bank Adjusts Pfizer PT to $43 From $38 on Significant Increa.. | MT |
| 05/10 | PFIZER : Morgan Stanley Adjusts Pfizer's Price Target to $42 From $38, Keeps Eq.. | MT |
| 05/06 | PFIZER : Mizuho Downgrades Pfizer to Neutral Rating From Buy, Price Target is $.. | MT |
| 05/05 | PFIZER : Goldman Sachs Adjusts Pfizer's Price Target to $45.11 From $43, Mainta.. | MT |
| 05/05 | PFIZER : JPMorgan Adjusts Pfizer's Price Target to $40 From $34.13, Maintains N.. | MT |
| 05/05 | PFIZER : SVB Leerink Adjusts Price Target on Pfizer to $43 From $39, Maintains .. | MT |
| 05/05 | PFIZER : Barclays Adjusts Pfizer's Price Target to $40 From $37, Keeps Equal-We.. | MT |
| 05/05 | PFIZER : RBC Capital Adjusts Pfizer's Price Target to $43 From $42, Keeps Secto.. | MT |
| 05/05 | PFIZER INC : Gets a Neutral rating from Barclays | MD |
| 03/31 | PFIZER INC : Goldman Sachs sticks Neutral | MD |
| 03/26 | PFIZER : SVB Leerink Adjusts Pfizer PT to $39 From $40, Maintains Market Perfor.. | MT |
| 03/23 | PFIZER : Berenberg Bank Adjusts Pfizer PT to $38 From $40, Maintains Hold Ratin.. | MT |
| 03/23 | PFIZER INC : Gets a Neutral rating from Berenberg | MD |
| 03/12 | PFIZER INC : Goldman Sachs sticks Neutral | MD |
| 03/09 | PFIZER INC : Goldman Sachs remains Neutral | MD |
| 02/04 | PFIZER : DZ Bank Upgrades Pfizer to Buy From Hold; Price Target is $41 | MT |
| 02/03 | CORRECTION : --Analyst Actions: Goldman Sachs Adjusts Price Target for UPS to $2.. | MT |
| 02/03 | CORRECTION : --Analyst Actions: Deutsche Bank Adjusts Price Target for UPS to $1.. | MT |
| 02/03 | PFIZER : Goldman Sachs Adjusts Price Target for Pfizer to $208 From $200, Maint.. | MT |
| 02/03 | PFIZER : Deutsche Bank Adjusts Price Target for Pfizer to $185 From $201, Maint.. | MT |
| 02/03 | PFIZER : Mizuho Adjusts Pfizer's Price Target to $42 From $44, Keeps Buy Rating | MT |
| 02/03 | PFIZER : SVB Leerink Adjusts Price Target on Pfizer to $40 From $41.71, Maintai.. | MT |
| 02/03 | PFIZER INC : DZ Bank raises its recommendation to Buy | MD |
| 02/02 | PFIZER INC : JP Morgan sticks Neutral | MD |
| 02/01 | PFIZER : RBC Capital Reiterates Pfizer Sector Perform Rating and $42 PT, Lookin.. | MT |
| 01/29 | PFIZER : Morgan Stanley Adjusts Pfizer's Price Target to $38 From $40, Keeps Eq.. | MT |
| 01/21 | PFIZER INC : Goldman Sachs reiterates its Neutral rating | MD |
| 01/08 | PFIZER INC : Goldman Sachs gives a Neutral rating | MD |
| 2020 | PFIZER INC : RBC remains Neutral | MD |
| 2020 | PFIZER : RBC Capital Downgrades Pfizer to Sector Perform From Outperform, Adjus.. | MT |
| 2020 | PFIZER INC : Goldman Sachs gives a Neutral rating | MD |
| 2020 | PFIZER INC : Goldman Sachs remains Neutral | MD |
| 2020 | PFIZER : FDA Panel Endorses Covid-19 Vaccine -- 7th Update | DJ |
| 2020 | PFIZER : FDA Panel Endorses Covid-19 Vaccine -- 6th Update | DJ |
| 2020 | PFIZER : FDA Panel Endorses Covid-19 Vaccine -- 5th Update | DJ |
| 2020 | PFIZER : FDA Advisory Panel Endorses Pfizer-BioNTech Covid-19 Vaccine -- 3rd Up.. | DJ |
| 2020 | WALL STREET WEEK AHEAD : After blazing energy rally, investors check the fuel ga.. | RE |
| 2020 | PFIZER : Barclays Adjusts Pfizer PT to $37 From $33.18, Maintains Equal Weight .. | MT |
| 2020 | German bond yields dip before U.S. jobs data, but set for biggest weekly rise.. | RE |
| 2020 | Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 7th Update | DJ |
| 2020 | PFIZER INC : Barclays sticks Neutral | MD |
| 2020 | UK approves Pfizer-BioNTech COVID-19 vaccine in world first | RE |
| 2020 | PFIZER INC : RBC gives a Buy rating | MD |
| 2020 | PFIZER INC : Gets a Neutral rating from Goldman Sachs | MD |
| 2020 | AstraZeneca Gears Up to Vaccinate the World Against Covid-19 | DJ |
| 2020 | AstraZeneca, Oxford Covid-19 Vaccine Up to 90% Effective in Late-Stage Trials.. | DJ |
| 2020 | Rand jumps despite ratings downgrade, EM stocks rally on vaccine hopes | RE |
| 2020 | PFIZER, GILEAD, ROSS : What to Watch When the Stock Market Opens Today | DJ |
| 2020 | PFIZER : Goldman Resumes Pfizer at Neutral With $40 Price Target | MT |
| 2020 | MACY'S, NVIDIA, SIMON PROPERTY GROUP : What to Watch When the Stock Market Opens.. | DJ |
| 2020 | NVIDIA, SIMON PROPERTY GROUP, BNY ME : What to Watch When the Stock Market Opens.. | DJ |
| 2020 | Pfizer Says Covid Vaccine Is 95% Effective in Final Data, Will Seek Authoriza.. | DJ |
| 2020 | Pfizer's Covid-19 Vaccine 95% Effective in Final Results, Company to Seek App.. | DJ |
| 2020 | Rate cut bets melt as vaccines boost economy hopes | RE |
| 2020 | Aramco Plans U.S. Dollar Bond to Plug Funding Gap -- Update | DJ |
| 2020 | PFIZER : Bernstein Reinstates Pfizer at Market Perform with $42 Price Target | MT |
| 2020 | Arcturus expects its COVID-19 vaccine to be ready by Q1 2021 | RE |
| 2020 | PFIZER : BioNTech Shares Hit 52-Week Highs on Covid-19 Vaccine Candidate News | DJ |
| 2020 | PFIZER INC : JP Morgan reaffirms its Neutral rating | MD |
| 2020 | PFIZER INC : Barclays remains Neutral | MD |
| 2020 | PFIZER : BioNTech Shares Rise After Positive News for Covid-19 Vaccine Candidat.. | DJ |
| 2020 | PFIZER INC : RBC reiterates its Buy rating | MD |
| 2020 | PFIZER INC : Buy rating from RBC | MD |
| 2020 | Exxon's Departure From Dow Highlights Market's Retreat From Energy Bets | DJ |
| 2020 | Top FDA official says would resign if agency rubber-stamps an unproven COVID-.. | RE |
| 2020 | Top FDA official says would resign if agency rubber-stamps an unproven COVID-.. | RE |
| 2020 | U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive | RE |
| 2020 | Moderna shares rise 11% on $1.5 billion U.S. contract for COVID-19 vaccine | RE |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
